(MENAFN- PR Newswire) BRISBANE, Australia, Aug. 23, 2021 /PRNewswire/ -- Immunexpress , Pty Ltd, a molecular diagnostic company founded in Brisbane, today announced that the SeptiCyte® RAPID test will ...
No combination of biomarkers outperformed SeptiScore ® alone, or models including SeptiScore ®, at identifying sepsis SEATTLE and BRISBANE, Australia, Jan. 22, 2024 /PRNewswire/ -- Immunexpress, Pty ...
SEATTLE and BRISBANE, Australia, Sept. 17, 2025 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the ...
SEATTLE, Sept. 22, 2016 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients and patients at risk of sepsis, announced today ...
SEATTLE, Nov. 17, 2020 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced further SeptiCyte® RAPID data ...
Growing clinical evidence from hospitalized coronavirus patients worldwide indicates that COVID-19 can quickly progress to viral sepsis or bacterial sepsis. The use of SeptiCyte® RAPID can help ...
SEATTLE, Aug. 23, 2022 /PRNewswire/ -- Immunexpress , Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the launch of new SeptiCyte ...
SeptiCyte®Lab is a rapid molecular assay that measures a patient’s gene expression level to differentiate between sepsis and infection-negative systemic inflammation. The manuscript describes the ...
Immunexpress Group, Debiopharm Group™ (Debiopharm) and Biocartis have announced a worldwide exclusive, royalty-bearing license for the late-stage development and commercialization of SeptiCyte® Triage ...
SEATTLE, May 9, 2018 /PRNewswire/ -- Immunexpress, Inc. today announced the publication in the American Journal of Respiratory and Clinical Care Medicine of the design and results of clinical trials ...
PERTH, Australia – The FDA has cleared Immunexpress Inc.’s 510(k) for its Septicyte rapid diagnostic test for sepsis that quantifies the relative expression levels of genes involved in a patient's ...
SEATTLE, Aug. 23, 2022 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the launch of new SeptiCyte ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback